Outpatient Oncology Infusion Market Analysis

Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors)

Infusion pumps segment is expected to account for outpatient oncology infusion market share of around 51.1% by 2036. The growth can be attributed to advances in technology, improved safety features, and the increasing shift towards outpatient and home-based treatments. Advanced infusion pumps provide high-precision drug delivery, which is critical for managing complex oncology treatments. This precision reduces the likelihood of dosage errors and ensures that patients receive the appropriate dose of medication. These pumps come with programmable features that allow healthcare providers to set specific infusion rates, delivery schedules, and dose adjustments. This flexibility is crucial for managing various chemotherapy regimens and individual patient needs.

Additionally, several infusion pump manufacturers are incorporating cutting-edge features, like wireless communication, connectivity to electronic health records, and compatibility with other medical devices. The key players are focused on accrediting approvals to launch new products and gain a competitive edge. For instance, in 2022, Baxter International Inc. received FDA approval for its revolutionary Novum IQ syringe infusion pump with Dose IQ Safety Software, which represents the company's most recent innovations in infusion therapy.

Application (Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer)

By 2036, lung cancer segment in the outpatient oncology infusion market is expected to cross USD 7.1 billion. Lung cancer (small cell and non-small cell) is the main cause of cancer-related mortality. A report by the American Cancer Society stated that in 2023, around 238,340 individuals were diagnosed with lung cancer, and 127,070 died from the disease in the United States.

The rise in lung cancer cases and the introduction of new therapies requiring frequent infusions drive the demand for outpatient infusion services. Many healthcare providers are expanding their outpatient infusion centers to meet this growing demand. Immunotherapies are increasingly used for lung cancer treatment, which generally involves outpatient infusions and is often part of long-term treatment plans.

Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy)

Chemotherapy segment is anticipated to account for outpatient oncology infusion market share of around 32.1% by 2036. Chemotherapy is used to treat a broad range of cancers, including breast, lung, colon, and lymphoma. Its widespread use ensures a high demand for infusion services. Many chemotherapy treatments require multiple cycles of infusions, which contributes to the need for ongoing outpatient care. Outpatient infusion allows patients to receive chemotherapy without the need for hospitalization, resulting in a better quality of life and less disruption to daily tasks. Patients are able to receive treatment in a less clinical and more comfortable setting, which can assist in reducing the psychological burden associated with cancer treatment.

Our in-depth analysis of the outpatient oncology infusion market includes the following segments: